Department of Hematology, The Fifth Medical Center of PLA General Hospital, Beijing, 100071, China; PLA 307 Clinical College of Anhui Medical University, Beijing, 100071, China.
Department of Hematology, The Fifth Medical Center of PLA General Hospital, Beijing, 100071, China.
Cancer Lett. 2023 Jan 28;553:215996. doi: 10.1016/j.canlet.2022.215996. Epub 2022 Nov 5.
V-set and immunoglobulin domain containing 4 (VSIG4), a type I transmembrane receptor exclusively expressed in a subset of tissue-resident macrophages, plays a pivotal role in clearing C3-opsonized pathogens and their byproducts from the circulation. VSIG4 maintains immune homeostasis by suppressing the activation of complement pathways or T cells and inducing regulatory T-cell differentiation, thereby inhibiting the development of immune-mediated inflammatory diseases but enhancing cancer progression. Consequently, VSIG4 exhibits a potential therapeutic effect for immune-mediated inflammatory diseases, but also is regarded as a novel target of immune checkpoint inhibition in cancer therapy. Recently, soluble VSIG4, the extracellular domain of VSIG4, shed from the surface of macrophages, has been found to be a biomarker to define macrophage activation-related diseases. This review mainly summarizes recent new findings of VSIG4 in macrophage phagocytosis and immune homeostasis, and discusses its potential diagnostic and therapeutic usage in infection, inflammation, and cancer.
V -set 和免疫球蛋白结构域蛋白 4（VSIG4）是一种仅在一组组织驻留巨噬细胞中表达的 I 型跨膜受体，在清除补体 C3 调理的病原体及其产物方面发挥着关键作用。VSIG4 通过抑制补体途径或 T 细胞的激活以及诱导调节性 T 细胞分化来维持免疫稳态，从而抑制免疫介导的炎症性疾病的发展，但促进癌症的进展。因此，VSIG4 对免疫介导的炎症性疾病具有潜在的治疗作用，但也被认为是癌症治疗中免疫检查点抑制的新靶点。最近，发现巨噬细胞表面脱落的可溶性 VSIG4（VSIG4 的细胞外结构域）是定义与巨噬细胞活化相关疾病的生物标志物。本文主要总结了 VSIG4 在巨噬细胞吞噬作用和免疫稳态方面的最新新发现，并讨论了其在感染、炎症和癌症中的潜在诊断和治疗用途。
